<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02929745</url>
  </required_header>
  <id_info>
    <org_study_id>15-17769</org_study_id>
    <nct_id>NCT02929745</nct_id>
  </id_info>
  <brief_title>Single Cell Genomics of Psoriatic Skin</brief_title>
  <official_title>Elucidating the Fundamental Differences Between HLA-Cw6 Positive and HLA-Cw6 Negative Psoriasis Skin Lesions, With a Comparison to Healthy Skin, at the Single Cell Level of the Infiltrated Immune Cell Types</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to understand how genetics play a role in psoriasis.&#xD;
      Specifically, a genetic allele HLA-Cw6 is known to be associated with psoriasis, and this&#xD;
      study aims to find out how it affects genetic and protein expression in patients with&#xD;
      psoriasis, compared to healthy people, at a single-cell level using a novel flow cytometry&#xD;
      and RNA-sequencing protocol.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 1, 2016</start_date>
  <completion_date type="Actual">December 9, 2020</completion_date>
  <primary_completion_date type="Actual">December 9, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of immune cell population from skin biopsies</measure>
    <time_frame>once</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determination of diferentially expressed genes from skin biopsies</measure>
    <time_frame>once</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of HLA -cw6 status from blood samples</measure>
    <time_frame>once</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>10 HLA-Cw6+</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HLA-Cw6+ patients will donate blood and skin samples</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 HLA Cw6-</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HLA-Cw6- patients will donate blood and skin samples</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Skin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy patients will donate blood and skin samples</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Skin biopsy</intervention_name>
    <description>Four 4-5 mm punch biopsies of the skin</description>
    <arm_group_label>10 HLA Cw6-</arm_group_label>
    <arm_group_label>10 HLA-Cw6+</arm_group_label>
    <arm_group_label>Healthy Skin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood draw</intervention_name>
    <description>Blood will be drawn to test for HLA-cw6 status</description>
    <arm_group_label>10 HLA Cw6-</arm_group_label>
    <arm_group_label>10 HLA-Cw6+</arm_group_label>
    <arm_group_label>Healthy Skin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        For subjects in the psoriasis group:&#xD;
&#xD;
          1. Ability to provide written consent and comply with the protocol&#xD;
&#xD;
          2. At least 18 years of age&#xD;
&#xD;
          3. Diagnosis of plaque psoriasis for at least 6 months prior to enrollment&#xD;
&#xD;
          4. BSA &gt; 5% and at least one target plaque on trunk or extremities greater than 10cm2&#xD;
&#xD;
        For control subjects:&#xD;
&#xD;
          1. Ability to provide written consent and comply with the protocol&#xD;
&#xD;
          2. At least 18 years of age&#xD;
&#xD;
          3. No previous diagnosis of psoriasis or other inflammatory skin conditions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        For subjects in the psoriasis group:&#xD;
&#xD;
          1. Subject has non-plaque form of psoriasis.&#xD;
&#xD;
          2. Subject has drug-induced psoriasis.&#xD;
&#xD;
          3. Pregnancy at any point during the study period.&#xD;
&#xD;
          4. Known allergy to lidocaine, other local anesthetics, or any component of local&#xD;
             anesthetic agents.&#xD;
&#xD;
          5. Known HIV positive status.&#xD;
&#xD;
          6. Evidence of abnormality of any immune cell population from a drug-induced or genetic&#xD;
             cause.&#xD;
&#xD;
          7. Known coagulopathy.&#xD;
&#xD;
        For control subjects:&#xD;
&#xD;
          1. Any physical examination findings by the investigators consistent with psoriasis or&#xD;
             other inflammatory skin conditions.&#xD;
&#xD;
          2. Pregnancy at any point during the study period.&#xD;
&#xD;
          3. Known allergy to lidocaine, other local anesthetics, or any component of local&#xD;
             anesthetic agents.&#xD;
&#xD;
          4. Known HIV positive status.&#xD;
&#xD;
          5. Evidence of abnormality of any immune cell population from a drug-induced or genetic&#xD;
             cause.&#xD;
&#xD;
          6. Known coagulopathy.&#xD;
&#xD;
          7. Use of any immunosuppressant or immunomodulating therapies within 6 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wilson Liao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Psoriasis Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Liu J, Chang HW, Huang ZM, Nakamura M, Sekhon S, Ahn R, Munoz-Sandoval P, Bhattarai S, Beck KM, Sanchez IM, Yang E, Pauli M, Arron ST, Fung-Leung WP, Munoz E, Liu X, Bhutani T, North J, Fourie AM, Rosenblum MD, Liao W. Single-cell RNA sequencing of psoriatic skin identifies pathogenic Tc17 cell subsets and reveals distinctions between CD8(+) T cells in autoimmunity and cancer. J Allergy Clin Immunol. 2021 Jun;147(6):2370-2380. doi: 10.1016/j.jaci.2020.11.028. Epub 2020 Dec 9.</citation>
    <PMID>33309739</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 7, 2016</study_first_submitted>
  <study_first_submitted_qc>October 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2016</study_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>immunology, genetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

